Skip to main content
. 2015 Dec 1;14:86. doi: 10.1186/s40200-015-0217-3

Table 5.

Pain measured using SF-MPQ in the studied groups

Baseline median (IQR) Placebo median (IQR) Drug median (IQR) Placebo pain difference median (IQR) Drug pain difference median (IQR) P-value*
Physical function (PF) 20(10) 25(13.75) 35(5) 5(10) 15(18.75) .018
Role Functioning (RF) 25(25) 25(50) 50(0) 0(25) 25(53.75) .026
Bodily pain (BP) 31(10) 41(16.50) 62(18.50) 11(10.50) 30.5(19.25) .001
General health (GH) 20(12) 35(28.75) 53.50(32.50) 10(19.50) 29(16) .001
Vitality (V) 27.50(8.75) 35(23.75) 55(28.75) 10(15) 25(8.75) .002
Social functioning (SF) 37.50(25) 50(9.37) 75(21.87) 12.50(12.50) 25(7.50) .005
Role-emotional (RE) 33.30(33.30) 66.70(33.40) 33.30(33.40) 33.30(33.40) 16.65(33.30) .333
Mental health (ME) 32(8) 42(18) 58(31) 8(9.50) 24(22.50) .002
Physical component summary (PCS) 26.05(5.05) 29.80(8.6) 38.35(11.85) 3.10(6.47) 11.45(12.27) .001
Mental component summary (MCS) 31.25(7.47) 39.70(8.9) 43.50(10.65) 5.55(5.77) 11.10(6.67) .012

Data are presented as median (interquartile range)

* P-value for drug difference and placebo difference according to Wilcoxon Signed Rank test

There is no difference in the baseline values between the two groups since it is a crossover study